ENGLEWOOD, Colo., Jan. 6, 2022 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE: AMPE), a biopharmaceutical
company focused on the advancement of immunology-based therapies
for prevalent inflammatory conditions, today announced that it
will present at the H.C. Wainwright Bioconnect Conference occurring
virtually on January 10-13, 2022.
Michael Martino, Chief Executive
Officer, will present an updated corporate overview of Ampio and
the presentation will be available on the event website beginning
at 7:00 a.m. ET on January 10, 2022.
Details can be found below:
Event: H.C. Wainwright Bioconnect Virtual Conference
Date: January 10-13, 2022
Location: Virtual
Event Website: https://hcwevents.com/bioconnect/
Investors participating in the conference who would like to
schedule a one-on-one meeting with Ampio's management may do so by
contacting an H.C. Wainwright representative.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company
primarily focused on the advancement of immunology-based therapies
to treat prevalent inflammatory conditions for which there are
limited treatment options. Ampio's lead drug, Ampion™, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2037 and may be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the Biologics
Price Competition and Innovation Act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to its use of the net proceeds from the
registered direct offering and its potential to realize future
proceeds from the exercise of warrants, Ampio's expectations with
respect to Ampion and its classification, the significance of the
top-line results from its clinical studies, including the AP-013
study, the FDA's acceptance of the company's analysis and or
interpretation of the results of its clinical trials, Ampio's cash
runway and ability to sustain operations for any given period of
time, the strength and enforceability of Ampio's patent portfolio
and its eligibility for FDA market exclusivity, the ability of
Ampio to enter into partnering arrangements, the potential market
for Ampion, the timing and likelihood of success of a BLA for
Ampion and other statements that are not purely statements of
historical fact. These forward-looking statements are made on the
basis of the current beliefs, expectations, and assumptions of
Ampio's management and are subject to significant risks and
uncertainties that could cause actual results to differ materially
from what may be expressed or implied in these forward-looking
statements. The risks and uncertainties involved include those
detailed from time to time in Ampio's filings with the Securities
and Exchange Commission, including without limitation, under
Ampio's Annual Report on Form 10-K and other documents filed with
the Securities and Exchange Commission. In addition, as stated in
the Company's filings with the Securities and Exchange Commission,
the FDA may determine that the COVID-19 pandemic may have impacted
its ability to interpret the Company's study results and may or may
not require additional studies in support of an Ampion BLA. Ampio
undertakes no obligation to revise or update these forward-looking
statements, whether, as a result of new information, future events
or otherwise.
Investor and Media Contacts:
Tony Russo or Nic
Johnson
Russo Partners
info@ampiopharma.com
tony.russo@russopartnersllc.com
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-presents-corporate-overview-at-hc-wainwright-bioconnect-conference-301455278.html
SOURCE Ampio Pharmaceuticals, Inc.